Top 5 Stocks to Buy Now
→ July 4th just killed solar and wind (From Behind the Markets) (Ad)tc pixel
NASDAQ:ENGN

enGene Q3 2025 Earnings Report

enGene logo
$1.69 -0.03 (-1.74%)
Closing price 04:00 PM Eastern
Extended Trading
$1.68 0.00 (-0.30%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

enGene EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

enGene Announcement Details

Quarter
Q3 2025
Date
9/11/2025
Time
Before Market Opens
Conference Call Date
Thursday, September 11, 2025
Conference Call Time
9:30AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

enGene Earnings Headlines

The V-8 engine isn’t going quietly—here’s every new car that still has one
 |  msn.comhttps://www.msn.com/en-us/autos/autos-luxury/the-v-8-engine-isn-t-going-quietly-here-s-every-new-car-that-still-has-one/ar-AA26i1L6
4 Common Problems With Inline-6 Engines
June 21 at 6:56 PM  |  msn.comhttps://www.msn.com/en-us/autos/general/4-common-problems-with-inline-6-engines/ar-AA26bG9g
July 4th just killed solar and wind
A law taking effect July 4th eliminates tax credits for every new solar and wind project in America. One energy source keeps full government backing for eight more years. It runs 24 hours a day, produces zero carbon, and requires no fuel. Google signed a 15-year contract. Bill Gates committed $100 million. The company behind it has been building this technology for sixty years, with revenue approaching $1 billion - yet Wall Street still prices it like a niche renewable.tc pixel
June 22 at 1:00 AM  |  Behind the Markets (Ad)
The Buick engine that created unexpected performance credibility
June 21 at 6:56 PM  |  msn.comhttps://www.msn.com/en-us/autos/news/the-buick-engine-that-created-unexpected-performance-credibility/ar-AA26bFu0
World’s first 100% hydrogen-fuelled marine engine delivering 2670kW power gets class approval
June 20 at 1:43 PM  |  msn.comhttps://www.msn.com/en-us/news/technology/world-s-first-100-hydrogen-fuelled-marine-engine-delivering-2670kw-power-gets-class-approval/ar-AA25Y80J
Why some diesel engines need wet cylinder sleeves, but they're rare in gas engines
June 20 at 1:43 PM  |  msn.comhttps://www.msn.com/en-us/autos/autos-trucks/why-some-diesel-engines-need-wet-cylinder-sleeves-but-they-re-rare-in-gas-engines/ar-AA266qvN
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN) is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

View enGene Profile
Earnings Tools